AnGes Inc
AnGes, Inc. engages in the research and development of gene-based medical products. It develops HGF gene therapy product for the treatment of ischemic diseases; NF-"B Decoy Oligo DNA for chronic discogenic lumber back pain; and DNA vaccines for the treatment of hypertension and cervical intraepithelial neoplasia, as well as intranasal formulation of the COVID-19 vaccine. The company was formerly … Read more
AnGes Inc (AMGXF) - Total Liabilities
Latest total liabilities as of June 2025: $2.38 Billion USD
Based on the latest financial reports, AnGes Inc (AMGXF) has total liabilities worth $2.38 Billion USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
AnGes Inc - Total Liabilities Trend (2017–2024)
This chart illustrates how AnGes Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
AnGes Inc Competitors by Total Liabilities
The table below lists competitors of AnGes Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Vaxart Inc
NASDAQ:VXRT
|
USA | $182.23 Million |
|
Anhui Hyea Aromas Co Ltd
SHE:300886
|
China | CN¥88.41 Million |
|
Dong Phu Rubber JSC
VN:DPR
|
Vietnam | ₫1.34 Trillion |
|
Avalue Technology
TWO:3479
|
Taiwan | NT$3.86 Billion |
|
Gix Internet Ltd
TA:ALMO
|
Israel | ILA75.48 Million |
|
iOCO Limited
JSE:IOC
|
South Africa | R2.37 Billion |
|
Dar Global Plc
LSE:DAR
|
UK | $1.48 Billion |
|
Brii Biosciences Limited
PINK:BRIBF
|
USA | $51.48 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down AnGes Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.09 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.70 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how AnGes Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for AnGes Inc (2017–2024)
The table below shows the annual total liabilities of AnGes Inc from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $2.51 Billion | -9.94% |
| 2023-12-31 | $2.79 Billion | -66.77% |
| 2022-12-31 | $8.40 Billion | +23.08% |
| 2021-12-31 | $6.82 Billion | +20.20% |
| 2020-12-31 | $5.67 Billion | +1109.36% |
| 2019-12-31 | $469.25 Million | +48.40% |
| 2018-12-31 | $316.21 Million | -7.47% |
| 2017-12-31 | $341.73 Million | -- |